
FDA Panel Overwhelmingly Rejects MDMA Psychedelic as Mental Health Treatment
CCHR applauds the panel’s decision amid concerns over biased clinical trials and risks such as heart attacks, strokes, psychosis, and sexual abuse of patients during…
CCHR applauds the panel’s decision amid concerns over biased clinical trials and risks such as heart attacks, strokes, psychosis, and sexual abuse of patients during…